Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-label, Phase II Study of Trastuzumab Emtansine in Patients With HER2-positive Metastatic Colorectal Cancer Progressing After Trastuzumab and Lapatinib: HERACLES RESCUE. (HER2 Amplification for Colo-rectaL Cancer Enhanced Stratification - REchallenge With her2 Selective Cytotoxic Uptake of Emtansine)

Next Previous
X
Search
Trial Profile

Open-label, Phase II Study of Trastuzumab Emtansine in Patients With HER2-positive Metastatic Colorectal Cancer Progressing After Trastuzumab and Lapatinib: HERACLES RESCUE. (HER2 Amplification for Colo-rectaL Cancer Enhanced Stratification - REchallenge With her2 Selective Cytotoxic Uptake of Emtansine)

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 05 Nov 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Trastuzumab emtansine (Primary)
  • Indications Adenocarcinoma; Colon cancer; Rectal cancer
  • Focus Proof of concept; Therapeutic Use
  • Acronyms HERACLES RESCUE; RESCUE

    • Most Recent Events

    • 13 Sep 2022 Status changed from recruiting to discontinued as per the results presented at the 47th European Society for Medical Oncology Congress.
    • 13 Sep 2022 Results presented at the 47th European Society for Medical Oncology Congress.
    • 21 Sep 2020 Results (n=92) of an analysis from HERACLES clinical program and other clinical trials assessing prevalence, timing of onset, and management of CNS recurrences in largest cohort of Colorectal cancer treated with anti-HER2 therapies at Niguarda Cancer Center presented at the 45th European Society for Medical Oncology Congress

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top